Poxel presents detailed positive data for imeglimin at EASD 2019

18 September 2019
poxel_large

Data presented in a symposium session at the annual meeting of the European Association for the Study of Diabetes (EASD) provide insights into imeglimin, an investigational type 2 diabetes medicine.

The candidate, which has a unique mechanism of action, is being developed by French metabolic diseases biotech company Poxel (Euronext: POXEL), in collaboration with Japan’s Sumitomo Dainippon Pharma (TYO: 4506).

Detailed Phase III results from the TIMES 1 program were presented at the symposium, showing the candidate achieved robust efficacy compared with placebo. Top-line data  released in April showed the trial met its primary and secondary endpoints.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology